Jakafi 5 MG tablet 60S
Ended Awarded Last action
- Contract number
- SPE2DR26FCRN8
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $24,793
Award facts
- Contract value 100% obligated
- $24,793.16 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $24,793.16 to DMS Pharmaceutical Group Inc. for 60 tablets of JAKAFI 5 mg, with an ultimate completion date of December 12, 2025. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected without a set-aside designation, demonstrating its competitive capability in unrestricted federal procurement. The delivery order was issued under the company's single-award Indefinite Delivery Contract (SPE2DR) established through the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to support recurring medical supply needs of military healthcare facilities worldwide.
This delivery order represents one of numerous awards issued to DMS Pharmaceutical Group under the PPV-G GEN V framework, which authorizes the Defense Logistics Agency to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products including branded and generic prescription drugs, biologics, and medical consumables. The parent indefinite delivery contract, valued at $499,999,999 with a completion date of December 31, 2036, positions DMS Pharmaceutical Group as a critical pharmaceutical supplier for Department of Defense healthcare operations globally. The company's established performance across multiple therapeutic categories and product lines demonstrates its capability to fulfill the specialized pharmaceutical requirements of the federal military medical system.
Quick answers
Who was awarded contract SPE2DR26FCRN8?
SPE2DR26FCRN8 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 11, 2025.
How much is contract SPE2DR26FCRN8 worth?
The government has obligated $24,793 on SPE2DR26FCRN8.
Is contract SPE2DR26FCRN8 an order under another contract?
Yes. SPE2DR26FCRN8 is a delivery order under SPE2DR25D9168, an indefinite delivery contract.
Was contract SPE2DR26FCRN8 competed?
The extent of competition for SPE2DR26FCRN8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award